<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Edrophonium (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Edrophonium (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Edrophonium (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="13266" href="/d/html/13266.html" rel="external">see "Edrophonium (United States: Not available): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F164261"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Acetylcholinesterase Inhibitor;</li>
<li>
                        Antidote;</li>
<li>
                        Diagnostic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F164246"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Enlon is no longer available in the United States.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c5b6043-3a50-44ec-a2cd-ebbfd60fce76">Diagnosis of myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnosis of myasthenia gravis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Methods vary in regards to the initial and repeat doses. However, all regimens utilize a maximum cumulative dose of 10 mg and emphasize that the incremental administration is to help avoid excessive muscarinic side effects. Atropine should be available at the bedside during the testing for the rare case in which severe bradycardia, cardiac arrhythmia, or hypotension develops. The following edrophonium dosing strategies have been described: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">2 mg; if after 90 seconds there is <i>definite</i> improvement, then test is considered positive and may be terminated. If symptoms recur, then may administer another 2 mg dose. If there is<i> no definite</i> improvement with the initial dose, then may administer 3 mg and observe patient for an additional 90 seconds; if test not positive, then may administer the remaining 5 mg and observe patient for 3 to 5 more minutes (Seybold 1986).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Or</b></p>
<p style="text-indent:-2em;margin-left:6em;">1 mg (test dose); if after 60 seconds there are no adverse effects, then administer 3 mg. If after 60 seconds there is no improvement, then administer an additional 3 mg; after an additional 60 seconds, repeat a 3 mg dose if necessary for a total dose of 10 mg (Pascuzzi 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer’s labeling: Dosing in the prescribing information may not reflect current clinical practice.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IV:</i> 2 mg test dose administered over 15 to 30 seconds; if no cholinergic reaction occurs after 45 seconds then administer 8 mg. If cholinergic reaction occurs after initial test dose, stop testing; test dose may be repeated after 30 minutes</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>IM: </i>10 mg; if cholinergic reaction occurs, administer 2 mg 30 minutes later to rule out false-negative reaction.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c98474a7-ca5b-444e-bd42-634a02bf8871">Evaluation of treatment requirements in myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Evaluation of treatment requirements in myasthenia gravis:</b>
<b>IV:</b> 1 to 2 mg given 1 hour after oral dose of anticholinesterase; response will be myasthenic in undertreated patients, adequate in the controlled patient, and cholinergic in the overtreated patient; adjust as appropriate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="48df2c03-1e71-48ca-a432-7bacfba1a025">Differentiation of cholinergic from myasthenic crisis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Differentiation of cholinergic from myasthenic crisis:</b>
<b>IV:</b> 1 mg; may repeat after 1 minute. <b>Note:</b> Intubation and controlled ventilation may be required if patient has cholinergic crisis.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b1d9b6e-fb5c-454e-bf4f-f289910d889f">Reversal of nondepolarizing neuromuscular blocking agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blocking agents: Note:</b> Atropine should be administered with edrophonium (or glycopyrrolate administered several minutes prior to edrophonium) to diminish the cholinergic effects, especially bradycardia (Barash 2009; Morgan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Usual dose: 0.5 to 1 mg/kg (Engbaek 1985; Miller 2010; Morgan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer’s labeling: <b>IV:</b> Dosing in the prescribing information may not reflect current clinical practice. 10 mg over 30 to 45 seconds; may repeat as necessary up to a maximum cumulative dose of 40 mg.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991082"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.  </p></div>
<div class="block doha drugH1Div" id="F50988367"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F164247"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F164254"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13266" href="/d/html/13266.html" rel="external">see "Edrophonium (United States: Not available): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Enlon is no longer available in the US.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c5b6043-3a50-44ec-a2cd-ebbfd60fce76">Diagnosis of myasthenia gravis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnosis of myasthenia gravis: Note:</b> Usually administered IV; if not possible, IM or SubQ may be used; however, the results are variable and it may take longer for reaction (Kliegman 2015). Atropine should be available at bedside during the testing for the rare case in which severe bradycardia, cardiac arrhythmia, or hypotension develops.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Test dose:</i> Limited data available: Some experts suggest an initial test dose to assess for hypersensitivity or sensitivity to muscarinic effects: IV: 0.01 mg/kg (Kliegman 2015; Swainman 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diagnostic dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer's labeling:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants: IV: 0.5 mg</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">≤34 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">IV: 1 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30 to 45 seconds to a total of 5 mg</p>
<p style="text-indent:-2em;margin-left:12em;">IM: 2 mg</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;34 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">IV: 2 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30 to 45 seconds to a total of 10 mg</p>
<p style="text-indent:-2em;margin-left:12em;">IM: 5 mg</p>
<p style="text-indent:-2em;margin-left:6em;">Alternate dosing: Weight-directed dosing: Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">IV, IM, SubQ: Initial: 0.01 to 0.02 mg/kg every 30 to 45 seconds up to the maximum dose (Kliegman 2015; Swaiman 2012). <b>Note:</b> Typical cumulative dose for a 3 to 5 year old is 5 mg/dose (Kliegman 2011)</p>
<p style="text-indent:-2em;margin-left:6em;">Maximum total dose (Kliegman 2015; Swaiman 2012):</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents: &lt;30 kg: 0.1 mg/kg</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥30 kg: 0.2 mg/kg or 10 mg; whichever is less</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b1d9b6e-fb5c-454e-bf4f-f289910d889f">Reversal of nondepolarizing neuromuscular blocking agents</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Reversal of nondepolarizing neuromuscular blocking agents:</b> Limited data available: Infants, Children, and Adolescents: IV: Usual dose: 0.5 to 1 mg/kg/dose; minimum dose: 0.3 mg/kg/dose (Cote 2013); doses studied range from 0.1 mg/kg to 1.43 mg/kg/dose (Bevan 1996; Fisher 1984; Kirkegaard-Nielsen 1995; Meakin 1983; Abdulatif 1996)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51107961"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51107962"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F164217"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for edrophonium.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Atrioventricular block, cardiac arrhythmia (especially bradycardia), cardiac arrest, ECG changes (nonspecific), flushing, hypotension, syncope, tachycardia, thrombophlebitis (IV)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Convulsions, dizziness, drowsiness, dysarthria, headache, loss of consciousness, voice disorder</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea, dysphagia, flatulence, hypersecretory conditions (gastric and intestinal), increased peristalsis, nausea, salivation, stomach cramps, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Urinary frequency, urinary urgency</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Fasciculations, laryngospasm, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Conjunctival hyperemia, diplopia, lacrimation, miosis, accommodation disturbance (spasm)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bronchoconstriction, increased bronchial secretions, respiratory arrest, respiratory paralysis</p></div>
<div class="block coi drugH1Div" id="F164231"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to edrophonium, sulfites, or any component of the formulation; GI or GU obstruction</p></div>
<div class="block war drugH1Div" id="F164215"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Cholinergic crisis: Overdosage can cause cholinergic crisis, which may be fatal.  Atropine should always be readily available as an antagonist and for treatment of cholinergic reactions. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Arrhythmias: Use with caution in patients with cardiac arrhythmias (eg, bradyarrhythmias) due to cholinergic effects.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Asthma: Use with caution in patients with bronchial asthma due to potential bronchoconstriction and/or increased secretions.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Myasthenia gravis:  Avoid use as an agent to reverse non-depolarizing neuromuscular blockade in patients with myasthenia gravis; may exacerbate muscular weakness.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Drug/drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult Drug Interactions database for more detailed information.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Sodium sulfite: Products may contain sodium sulfite.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878439"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Edrophonium is not recommended for use in infants; its effect is too brief for objective assessment and may have an increased risk of acute cardiac arrhythmias in infants, especially neonates (Kliegman 2015).</p></div>
<div class="block prod-avail drugH1Div" id="F51722616"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Enlon is no longer available in the US.</p></div>
<div class="block geq drugH1Div" id="F164211"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323126"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Enlon Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $6.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F164228"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Injection: May administer undiluted by IV, IM, or SubQ injection; refer to individual indications in dosing for detailed recommendations.</p></div>
<div class="block admp drugH1Div" id="F52612668"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Edrophonium is administered by direct IV or IM injection; if not possible, SubQ may be used.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Diagnosis of myasthenia gravis: Administer as IV Push; in adults, doses have been administered over 15 to 30 seconds and follow with a saline flush (Pascuzzi 2003)</p></div>
<div class="block use drugH1Div" id="F164227"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">Diagnosis of myasthenia gravis; differentiation of cholinergic crises from myasthenia crises; reversal of nondepolarizing neuromuscular blockers</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Although the onset of action of neostigmine is delayed, the use of neostigmine (with glycopyrrolate) is usually preferred over edrophonium for the reversal of nondepolarizing neuromuscular blockers due to a longer duration of action (Barash 2009; Morgan 2013).</p></div>
<div class="block cyt drugH1Div" id="F13299253"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F164219"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Edrophonium may enhance the AV-blocking effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Chlorprothixene. Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Acetylcholinesterase Inhibitors may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F21024362"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Due to the theoretical potential for complications, consider a lower initial dose when using edrophonium for the diagnosis of myasthenia gravis during pregnancy (Varner, 2013).</p></div>
<div class="block brc drugH1Div" id="F20617081"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if edrophonium is excreted in breast milk. According to the Canadian manufacturer, the decision to breast-feed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F164223"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Pre- and postinjection strength (cranial musculature is most useful); heart rate, respiratory rate, blood pressure</p></div>
<div class="block pha drugH1Div" id="F164214"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits destruction of acetylcholine by acetylcholinesterase. This facilitates transmission of impulses across myoneural junction and results in increased cholinergic responses such as miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions.</p></div>
<div class="block phk drugH1Div" id="F164230"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: IM: 2 to 10 minutes; IV: 30 to 60 seconds</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: IM: 5 to 30 minutes: IV: 10 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: Infants: 1.18 ± 0.2 L/kg; Children: 1.22 ± 0.74 L/kg; Adults: 0.9 ± 0.13 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Infants: 73 ± 30 minutes; Children: 99 ± 31 minutes; Adults: 126 ± 59 minutes; Anephric patients: 2.4 to 4.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Adults: Primarily urine (67%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Infants: 17.8 mL/kg/minute; Children: 14.2 mL/kg/minute; Adults: 8.3 ± 2.9 mL/kg/minute</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038609"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Enlon</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anticude</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Enlon | Reversol | Tensilon</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Edrophonium | Tensilon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Antirex</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Enlon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Enlon</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Enlon | Tensilon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Enlon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-8777104">
<a name="8777104"></a>Abdulatif M, Al-Ghamdi A, Al-Sanabary M, Abdel-Gaffar ME. Edrophonium antagonism of intense mivacurium-induced neuromuscular block in children. <i>Br J Anaesth</i>. 1996;76(2):239-244.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/8777104/pubmed" id="8777104" target="_blank">8777104</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Avery, GB, Fletcher, MA, MacDonald MG, eds. Neonatology: Pathophysiology and Management of the Newborn. 4th ed. Philadelphia, PA: J. B. Lippincott Company; 1994.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6869871">
<a name="6869871"></a>Azar I, Pham AN, Karamkekar, et al, “The Heart Rate Following Edrophonium-Atropine and Edrophonium Glycopyrrolate Mixtures,” <i>Anesthesiology</i>, 1983, 59(2):139-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/6869871/pubmed" id="6869871" target="_blank">6869871</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Barash PG, Cullen BF, Stoelting RK, et al, eds. <i>Clinical Anesthesia</i>. 6th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8602667">
<a name="8602667"></a>Bevan DR, Kahwaji R, Ansermino JM, Reimer E, Smith MF, O'Connor GA, Bevan JC. Residual block after mivacurium with or without edrophonium reversal in adults and children. <i>Anesthesiology</i>. 1996;84(2):362-367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/8602667/pubmed" id="8602667" target="_blank">8602667</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Butterworth J, Mackey DC, Wasnick J, <i>Clinical Anesthesiology</i>, 5th ed, New York, NY; McGraw-Hill, 2013.</div>
</li>
<li>
<div class="reference">
                  Coté CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia Children</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7037027">
<a name="7037027"></a>Cronnely R and Morris RB, “Antagonism of Neuromuscular Blockade,” <i>Br J Anaesth</i>, 1982, 54(2):183-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/7037027/pubmed" id="7037027" target="_blank">7037027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2863917">
<a name="2863917"></a>Engbaek J, Ording H, Ostergaard D, Viby-Mogensen J. Edrophonium and neostigmine for reversal of the neuromuscular blocking effect of vecuronium. <i>Acta Anaesthesiol Scand.,</i> 1985;29(5):544-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/2863917/pubmed" id="2863917" target="_blank">2863917</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Enlon (edrophonium) [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6486504">
<a name="6486504"></a>Fisher DM, et al. Clinical Pharmacology of Edrophonium in Infants and Children. <i>Anesthesiology</i>. 1984;61(4):428-433.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/6486504/pubmed" id="6486504" target="_blank">6486504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8848890">
<a name="8848890"></a>Kirkegaard-Nielsen H, Meretoja OA, Wirtavuori K. Reversal of atracurium-induced neuromuscular block in paediatric patients. <i>Acta Anaesthesiol Scand</i>. 1995;39(7):906-911.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/8848890/pubmed" id="8848890" target="_blank">8848890</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6311057">
<a name="6311057"></a>Meakin G, Sweet PT, Bevan JC, Bevan DR. Neostigmine and edrophonium as antagonists of pancuronium in infants and children. <i>Anesthesiology</i>. 1983;59(4):316-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/6311057/pubmed" id="6311057" target="_blank">6311057</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Miller RD. <i>Miller’s Anesthesia, </i>7th ed. Philadelphia PA: Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” <i>Chest</i>, 2003, 123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1573230">
<a name="1573230"></a>Papazian O. Transient neonatal myasthenia gravis. <i>J Child Neurol</i>. 1992;7(2):135-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/1573230/pubmed" id="1573230" target="_blank">1573230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12870109">
<a name="12870109"></a>Pascuzzi RM. The edrophonium test. <i>Semin Neurol</i>. 2003;23(1):83-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/12870109/pubmed" id="12870109" target="_blank">12870109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-765513">
<a name="765513"></a>Rossen RN, Krikorian J, and Hancock EW, “Ventricular Asystole After Edrophonium Chloride Administration,” <i>JAMA</i>, 1976, 235(10):1041-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/765513/pubmed" id="765513" target="_blank">765513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911480">
<a name="22911480"></a>Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. <i>Neuropediatrics</i>. 2012;43(4):184-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/22911480/pubmed" id="22911480" target="_blank">22911480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3729766">
<a name="3729766"></a>Seybold ME. The office Tensilon test for ocular myasthenia gravis. <i>Arch Neurol</i>. 1986;43(8):842-843.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/3729766/pubmed" id="3729766" target="_blank">3729766</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Swaiman KF, Ashwal S, Ferriero DM, Schor NF, eds. <i>Swaiman's Pediatric Neurology: Principles and Practice</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2012.</div>
</li>
<li>
<div class="reference">
                  Tensilon (edrophonium) [Canadian product monograph]. Montreal, Quebec, Canada: Valeant Canda Limited; June, 2005.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23563874">
<a name="23563874"></a>Varner M. Myasthenia gravis and pregnancy. <i>Clin Obstet Gynecol</i>. 2013;56(2):372-381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/23563874/pubmed" id="23563874" target="_blank">23563874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-434509">
<a name="434509"></a>Youngberg JA, “Cardiac Arrest Following Treatment of Paroxysmal Atrial Tachycardia With Edrophonium,” <i>Anesthesiology</i>, 1979, 50(3):234-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/edrophonium-united-states-not-available-drug-information/abstract-text/434509/pubmed" id="434509" target="_blank">434509</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9403 Version 180.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
